131616Novel therapeutic antibodies against nf-P2X7ClosedFeasibility StudiesInnovate UKIn December 2013 the World Health Organization, released data showing that globally there were 14.1 million new cases of cancer and 8.2 million cancer deaths in 2012. Significant medical progress has been made, but patient outcomes remain poor, new cancer cases are increasing and for certain types of cancer, existing treatment options and those in development are clearly inadequate. Bioseptre, a company developing cancer therapeutics in the UK, has discovered nf-P2X7, a unique varient of P2X7, an important cell protein present in cancer cells, that can be used to target cancers in order to kill them. This project will build on existing data to confirm that it is possible to create an innovative biological therapeutic that can be used to treat patients. Because of its mechanism of action, this therapeutic will have the potential to treat multiple cancer types safely.